Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, and Sato Pharmaceutical Co., Ltd., a leading pharmaceutical company, today announced that the companies have entered into a strategic collaboration and licensing agreement for the development, manufacture, and commercialization of topical roflumilast in Japan.

Arcutis Biotherapeutics，Inc.（纳斯达克：ARQT），一家商业阶段的生物制药公司，专注于在免疫皮肤病学领域开发有意义的创新，以及领先的制药公司佐藤制药有限公司，今天宣布，两家公司已就开发达成战略合作和许可协议，日本局部罗氟司特的制造和商业化。

Sato will receive an exclusive license for both the cream and foam formulations of topical roflumilast, a next generation phosphodiesterase type 4 (PDE4) inhibitor, for multiple dermatological conditions including plaque psoriasis, seborrheic dermatitis, atopic dermatitis, and potentially additional dermatological conditions in the future.

佐藤将获得下一代磷酸二酯酶4型（PDE4）抑制剂局部罗氟司特乳膏和泡沫制剂的独家许可，用于多种皮肤病，包括斑块状牛皮癣，脂溢性皮炎，特应性皮炎以及未来可能出现的其他皮肤病。

“We are delighted to partner with Sato, who share our mission to provide meaningful innovation to individuals suffering from immune-mediated skin diseases. This partnership, built on topical roflumilast’s strong product profile, expands the market opportunity for this effective and well-tolerated steroid-free treatment for multiple skin conditions, and provides meaningful non-dilutive capital for us,” said Frank Watanabe, president and chief executive officer, Arcutis.

“我们很高兴与佐藤合作，佐藤的使命是为患有免疫介导的皮肤病的个体提供有意义的创新。这种合作关系建立在局部罗氟司特强大的产品简介的基础上，扩大了这种有效且耐受性良好的无类固醇治疗多种皮肤病的市场机会，并提供了有意义的非稀释性资本阿库蒂斯总裁兼首席执行官弗兰克·渡边（FrankWatanabe）表示。

“Sato’s enduring corporate commitment to helping patients achieve a more positive and enjoyable life makes them an ideal partner .

“佐藤长期致力于帮助患者实现更积极和愉快的生活，这使他们成为理想的伴侣。